|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sklenicka S, Gardiner S, Dierks EJ, Potter
BE and Bell RB: Survival analysis and risk factors for recurrence
in oral squamous cell carcinoma: Does surgical salvage affect
outcome? J Oral Maxillofac Surg. 68:1270–1275. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dissanayaka WL, Pitiyage G, Kumarasiri PV,
Liyanage RL, Dias KD and Tilakaratne WM: Clinical and
histopathologic parameters in survival of oral squamous cell
carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 113:518–525.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen YK, Huang HC, Lin LM and Lin CC:
Primary oral squamous cell carcinoma: An analysis of 703 cases in
southern Taiwan. Oral Oncol. 35:173–179. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fioretti F, Bosetti C, Tavani A,
Franceschi S and La Vecchia C: Risk factors for oral and pharyngeal
cancer in never smokers. Oral Oncol. 35:375–378. 1999. View Article : Google Scholar
|
|
6
|
Altieri A, Bosetti C, Gallus S, Franceschi
S, Dal Maso L, Talamini R, Levi F, Negri E, Rodriguez T and La
Vecchia C: Wine, beer and spirits and risk of oral and pharyngeal
cancer: A case-control study from Italy and Switzerland. Oral
Oncol. 40:904–909. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kolanjiappan K, Ramachandran CR and
Manoharan S: Biochemical changes in tumor tissues of oral cancer
patients. Clin Biochem. 36:61–65. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kaur J, Politis C and Jacobs R: Salivary
8-hydroxy-2-deoxyguanosine, malondialdehyde, vitamin C, and vitamin
E in oral pre-cancer and cancer: diagnostic value and free radical
mechanism of action. Clin Oral Investig. 20:315–319. 2016.
View Article : Google Scholar
|
|
9
|
Block K and Gorin Y: Aiding and abetting
roles of NOX oxidases in cellular transformation. Nat Rev Cancer.
12:627–637. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Weyemi U, Redon CE, Parekh PR, Dupuy C and
Bonner WM: NADPH oxidases NOXs and DUOXs as putative targets for
cancer therapy. Anticancer Agents Med Chem. 13:502–514. 2013.
|
|
11
|
Sancho P and Fabregat I: NADPH oxidase
NOX1 controls autocrine growth of liver tumor cells through
up-regulation of the epidermal growth factor receptor pathway. J
Biol Chem. 285:24815–24824. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Momose F, Araida T, Negishi A, Ichijo H,
Shioda S and Sasaki S: Variant sublines with different metastatic
potentials selected in nude mice from human oral squamous cell
carcinomas. J Oral Pathol Med. 18:391–395. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nakaoka T, Ota A, Ono T, Karnan S, Konishi
H, Furuhashi A, Ohmura Y, Yamada Y, Nakaoka T, Ota A, Ono T, Karnan
S, Konishi H, Furuhashi A, Ohmura Y, Yamada Y, Hosokawa Y and
Kazaoka Y: Combined arsenic trioxide-cisplatin treatment enhances
apoptosis in oral squamous cell carcinoma cells. Cell Oncol.
37:119–129. 2014. View Article : Google Scholar
|
|
14
|
Hossain E, Ota A, Karnan S, Damdindorj L,
Takahashi M, Konishi Y, Konishi H and Hosokawa Y: Arsenic augments
the uptake of oxidized LDL by upregulating the expression of
lectin-like oxidized LDL receptor in mouse aortic endothelial
cells. Toxicol Appl Pharmacol. 273:651–658. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Takahashi M, Ota A, Karnan S, Hossain E,
Konishi Y, Damdindorj L, Konishi H, Yokochi T, Nitta M and Hosokawa
Y: Arsenic trioxide prevents nitric oxide production in
lipopolysac-charide -stimulated RAW 264.7 by inhibiting a
TRIF-dependent pathway. Cancer Sci. 104:165–170. 2013. View Article : Google Scholar
|
|
16
|
Ralph SJ, Rodríguez-Enríquez S, Neuzil J,
Saavedra E and Moreno-Sánchez R: The causes of cancer revisited:
'mitochondrial malignancy' and ROS-induced oncogenic transformation
- why mitochondria are targets for cancer therapy. Mol Aspects Med.
31:145–170. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mochizuki T, Furuta S, Mitsushita J, Shang
WH, Ito M, Yokoo Y, Yamaura M, Ishizone S, Nakayama J, Konagai A,
et al: Inhibition of NADPH oxidase 4 activates apoptosis via the
AKT/apoptosis signal-regulating kinase 1 pathway in pancreatic
cancer PANC-1 cells. Oncogene. 25:3699–3707. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tanaka M, Miura Y, Numanami H, Karnan S,
Ota A, Konishi H, Hosokawa Y and Hanyuda M: Inhibition of NADPH
oxidase 4 induces apoptosis in malignant mesothelioma: Role of
reactive oxygen species. Oncol Rep. 34:1726–1732. 2015.PubMed/NCBI
|
|
19
|
Zhang B, Liu Z and Hu X: Inhibiting cancer
metastasis via targeting NAPDH oxidase 4. Biochem Pharmacol.
86:253–266. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Puca R, Nardinocchi L, Starace G, Rechavi
G, Sacchi A, Givol D and D'Orazi G: Nox1 is involved in p53
deacetylation and suppression of its transcriptional activity and
apoptosis. Free Radic Biol Med. 48:1338–1346. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fletcher EV, Love-Homan L, Sobhakumari A,
Feddersen CR, Koch AT, Goel A and Simons AL: EGFR inhibition
induces proinflammatory cytokines via NOX4 in HNSCC. Mol Cancer
Res. 11:1574–1584. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Orcutt KP, Parsons AD, Sibenaller ZA,
Scarbrough PM, Zhu Y, Sobhakumari A, Wilke WW, Kalen AL, Goswami P,
Miller FJ Jr, et al: Erlotinib-mediated inhibition of EGFR
signaling induces metabolic oxidative stress through NOX4. Cancer
Res. 71:3932–3940. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fumarola C, Bonelli MA, Petronini PG and
Alfieri RR: Targeting PI3K/AKT/mTOR pathway in non small cell lung
cancer. Biochem Pharmacol. 90:197–207. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Barrett D, Brown VI, Grupp SA and Teachey
DT: Targeting the PI3K/AKT/mTOR signaling axis in children with
hematologic malignancies. Paediatr Drugs. 14:299–316.
2012.PubMed/NCBI
|
|
25
|
Simpson DR, Mell LK and Cohen EE:
Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of
the head and neck. Oral Oncol. 51:291–298. 2015. View Article : Google Scholar
|
|
26
|
Kozaki K, Imoto I, Pimkhaokham A, Hasegawa
S, Tsuda H, Omura K and Inazawa J: PIK3CA mutation is an oncogenic
aberration at advanced stages of oral squamous cell carcinoma.
Cancer Sci. 97:1351–1358. 2006. View Article : Google Scholar : PubMed/NCBI
|
